Sanofi overview
Sanofi contact information
Offices
54, rue La Boétie, Paris, 75008, FranceContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Mr. Felix Lauscher | Job titleHead of Investor Relations | LocationBridgewater, United States | Email  ----------- |
| Key ContactMs. Alba Zurriaga Carda | Job titleDirector of Investments | LocationCambridge, United States | Email ----- |
| Mr. Jason P. Hafler | Job titleManaging Director - Sanofi Ventures | LocationCambridge, United States | Email ---------- |
| Ms. Nina Goworek | Job titleVice President, Head of Investor Relations North America | LocationCambridge, United States | Email -------- |
Sanofi fund commitments
Known fund commitments: 8
| Fund | Manager | Commitment date | Commitment size |
|---|---|---|---|
Manager -------- | Commitment date- | Commitment size- | |
Manager -------- | Commitment date- | Commitment size ------ | |
Manager ----------- | Commitment date- | Commitment size ------- | |
Stories that mention Sanofi
A-Z of Healthcare: L-P
The third part of our A-Z looks at logistics, mental health, nursing homes, outcomes and pharmaceuticals.
France's Cathay Capital founder: LPs are pushing us to launch impact fund
The firm held a final close on Cathay Innovation Fund II on €650m last month, more than doubling the firepower of its 2016-vintage Fund I, founder MingPo Cai tells PEI.
Warburg Pincus improves liquidity in blood company
Over nearly seven years, Warburg more than doubled EBITDA at China Biologic Products and created a booming plasma-based drugs company.
Hanspeter Spek joins Advent’s operations network
Pharmaceutical giant Sanofi's former president of global operations is the latest addition to Advent’s 60-strong operating partner programme.
Report: Suitors found for Sequoia and Actis' Paras
Morgan Stanley has reportedly found five potential trade buyers for the firms' 70% stake in Paras Pharmaceuticals, which is valued at $700m.
Sofinnova head heralds strength of French life sciences
As the Paris-based venture firm rings out the old year with another exit – its third to break the $500m mark during 2009 – managing partner Denis Lucquin hails ‘the depth of French life sciences innovation’.
Sofinnova heads for a healthy year of exits
Two successful exits – one of which achieved a 6.6x multiple – and two more in the pipeline should help the French venture firm push its latest fundraising effort over the finish line.
Accel-KKR invests in medical software maker
IntrinsiQ, a maker of medical oncology care software, will be the first investment for Accel-KKR in the healthcare information technology sector.